Evidence map›Paper›PMID 29103750›Full record

ReviewOral oncology2017

Salivary duct carcinoma: An aggressive salivary gland malignancy with opportunities for targeted therapy.

Nicole C Schmitt, Hyunseok Kang, Arun Sharma

Open access · greenAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Oral oncology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 45 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
45citing papers in PubMed, 1 pooled it
8.2field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

45 citing papers in PubMed, 1 synthesis or guideline pooled it, 108 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Salivary gland-type cancers: cross-organ demographics of a rare cancer.International journal of clinical oncology · 2024
    Article
  14. Article
  15. Review
  16. Article
  17. Prognostic models for estimating survival of salivary duct carcinoma: a population-based study.European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery · 2023
    Article
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 3 institutions in 1 country.

Nicole C SchmittIntegrative Therapeutics Program, National Institute on Deafness and Other Communication Disorders, National Institutes of Health, Bethesda, MD, United States; Department of Otolaryngology - Head and Neck Surgery, Johns Hopkins University, Bethesda, MD, United States. Electronic address: Nschmit4@jhmi.edu.
Hyunseok KangDepartment of Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins Medical Institutions, Baltimore, MD, United States.
Arun SharmaDivision of Otolaryngology - Head and Neck Surgery, Southern Illinois University, Springfield, IL, United States.
Johns Hopkins University · USNational Institutes of Health · USSouthern Illinois University School of Medicine · US

Funding

Mechanisms and Optimal Combinations of Cisplatin Chemotherapy for Head and Neck Squamous Cell CarcinomaZIADC000090 · NIDCD · NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS · PI SCHMITT, NICOLE · 2016 to 2020
$3.9M
Intramural NIH HHS ZIA DC000090
6 · The paper itself

Abstract

Salivary duct carcinoma (SDC) is a rare, aggressive salivary malignancy that is often diagnosed at an advanced stage. Previously, little was known about outcomes of this disease due to its rarity. In the past several years, much has been learned about salivary duct carcinoma after publication of outcomes from several large single-institution series and national database searches. Recent studies of genomic alterations have helped elucidate the biology and pathogenesis of this aggressive disease. Here we review outcomes of the disease, effects of treatment, prognostic factors, and genomic alterations in SDC. Studies of targeted therapy and promising future directions are also discussed.

Indexed as

AdultFemaleHumansMaleMutationPrognosisSalivary DuctsSalivary Gland NeoplasmsSurvival AnalysisErbB2Salivary duct carcinomaSalivary malignancy

Identifiers

PMID29103750
PMCPMC5685667
OpenAlexW2758417871

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.